Whitehawk Therapeutics Inc (WHWK) Stock Analysis & Investment Frameworks
Whitehawk Therapeutics Inc (WHWK) stock analysis on Invetso. Review Whitehawk Therapeutics Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Whitehawk Therapeutics Inc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Whitehawk Therapeutics Inc Key Financial Metrics
- Market Cap: $186.99M
- Revenue: $7.14M
- ROE: -53.89%
- ROIC: -47.05%
- Dividend Yield: N/A
About Whitehawk Therapeutics Inc
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Whitehawk Therapeutics Inc Investment Frameworks
Invetso analyzes Whitehawk Therapeutics Inc (WHWK) across the following frameworks:
- Whitehawk Therapeutics Inc 10Y Growth Potential
- Whitehawk Therapeutics Inc Scenario Analysis
- Whitehawk Therapeutics Inc Risks & Opportunities
- Whitehawk Therapeutics Inc Economic Moat
- Whitehawk Therapeutics Inc Business Model
- Whitehawk Therapeutics Inc Management
- Whitehawk Therapeutics Inc SWOT Analysis
- Whitehawk Therapeutics Inc Porter's 5 Forces
- Whitehawk Therapeutics Inc PESTLE Analysis
- Whitehawk Therapeutics Inc ESG Analysis